Company / Cash & Equivalents
ORTHOPEDIATRICS CORP Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$19.6M
FY2025
5-year range
$7.6M / $43.8M
FY2021-FY2025
Trend
-55.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 8 years, ranging from $4M in FY2017 to $71M in FY2019.
Based on SEC 10-K filings.
$20M in FY2025 with a 5-year CAGR of -7.4%.
Declined from $31M to $20M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -7.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -7.4%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 55.4% year-over-year.
- Peak cash & equivalents was recorded in FY2019.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.6M | -55.4% |
| FY2024 | $43.8M | +41.1% |
| FY2023 | $31.1M | - |
| FY2022 | - | - |
| FY2021 | $7.6M | -73.4% |
| FY2020 | $28.8M | -59.4% |
| FY2019 | $70.8M | +16.6% |
| FY2018 | $60.7M | +1465.0% |
| FY2017 | $3.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026